ACTU ACTUATE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ACTUATE THERAPEUTICS INC reported revenue of n/a, net income of −$4.87M and diluted EPS of −$0.20; for the fiscal year ended December 2025 revenue was n/a.
ACTU annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$22.5M, net income −$22.2M (margin n/a), EPS −$1.06
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$25.2M, net income −$27.3M (margin n/a), EPS −$3.26
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$25.0M, net income −$24.7M (margin n/a), EPS −$17.24
ACTU quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.87M, EPS −$0.20
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.63M, EPS −$0.24
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$4.55M, EPS −$0.19
- Quarter ended Sep 30, 2025: revenue n/a, net income −$5.41M, EPS −$0.25
- Quarter ended Jun 30, 2025: revenue n/a, net income −$5.95M, EPS −$0.30
- Quarter ended Mar 31, 2025: revenue n/a, net income −$6.32M, EPS −$0.32
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$6.45M, EPS $6.89
- Quarter ended Sep 30, 2024: revenue n/a, net income −$5.97M, EPS −$0.55
- Quarter ended Jun 30, 2024: revenue n/a, net income −$6.57M, EPS −$4.20
- Quarter ended Mar 31, 2024: revenue n/a, net income −$8.30M, EPS −$5.40
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$7.61M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$6.34M, EPS −$4.31
- Quarter ended Jun 30, 2023: revenue n/a, net income −$5.52M, EPS −$3.88
- Quarter ended Mar 31, 2023: revenue n/a, net income −$5.27M, EPS n/a
ACTU cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$19.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$21.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$21.6M, share buybacks n/a
ACTU balance sheet
- Jun 30, 2026: cash $4.43M, total assets $5.20M, total liabilities $4.21M, shareholders' equity $989K
- Mar 31, 2026: cash $8.13M, total assets $8.91M, total liabilities $5.13M, shareholders' equity $3.78M
- Dec 31, 2025: cash $13.2M, total assets $14.0M, total liabilities $6.11M, shareholders' equity $7.92M
- Sep 30, 2025: cash $16.9M, total assets $17.7M, total liabilities $6.78M, shareholders' equity $10.9M
- Jun 30, 2025: cash $6.49M, total assets $6.97M, total liabilities $9.62M, shareholders' equity −$2.65M
- Mar 31, 2025: cash $3.89M, total assets $4.48M, total liabilities $9.57M, shareholders' equity −$5.09M
- Dec 31, 2024: cash $8.64M, total assets $9.32M, total liabilities $9.21M, shareholders' equity $104K
- Sep 30, 2024: cash $13.5M, total assets $14.3M, total liabilities $8.90M, shareholders' equity $5.36M
Is ACTU profitable?
No. ACTUATE THERAPEUTICS INC lost $20.5M over the last four quarters.
What is ACTU's EPS?
Diluted earnings per share over the last four quarters were −$0.88; −$0.20 in the latest quarter.